Sinclair Pharma (XPAR:SPH) Common Stock : €5.74 Mil (As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Common Stock?

Sinclair Pharma's quarterly common stock declined from Jun. 2017 (€5.74 Mil) to Dec. 2017 (€5.71 Mil) but then increased from Dec. 2017 (€5.71 Mil) to Jun. 2018 (€5.74 Mil).

Sinclair Pharma's annual common stock increased from Jun. 2014 (€6.19 Mil) to Jun. 2015 (€6.90 Mil) but then declined from Jun. 2015 (€6.90 Mil) to Dec. 2017 (€5.71 Mil).

Sinclair Pharma Common Stock Historical Data

The historical data trend for Sinclair Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma Common Stock Chart

Sinclair Pharma Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Dec17

Common Stock

Get a 7-Day Free Trial

4.99

5.11

6.19

6.90

5.71

Sinclair Pharma Semi-Annual Data
	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Jun17	Dec17	Jun18
Common Stock	Get a 7-Day Free Trial															6.84	6.29	5.74	5.71	5.74

Sinclair Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Sinclair Pharma (XPAR:SPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sinclairispharma.com

Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.